questionText: To ask the Secretary of State for Health and Social Care, what assessment he has made of the effectiveness of the Early Access to Medicines Scheme in facilitating patient access to new treatments for neuromuscular diseases.
answerText: The Medicines and Healthcare products Regulatory Agency (MHRA) supports access to treatments for people living with neuromuscular diseases. The majority of neuromuscular diseases are defined as rare diseases. On the 2 November 2025, the MHRA published a p...
heading: Neurological Diseases: Drugs